Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Vector Borne Zoonotic Dis ; 24(9): 607-613, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38946629

RESUMEN

Background: Tick-borne encephalitis (TBE) is caused by the tick-borne encephalitis virus (TBEV). TBEV infection can cause symptoms of central nervous system (CNS) inflammation and result in severe consequences including death. TBE is an increasing health threat in the Czech Republic and elsewhere in Europe. In 2020, 23% of 3734 TBE cases reported to the European Centre for Disease Prevention and Control were from the Czech Republic. TBE vaccination is universally recommended in the Czech Republic, but a full analysis of TBE vaccine effectiveness (VE) in the Czech Republic has not been published. Methods: TBE is a notifiable disease in the Czech Republic with mandatory reporting of cases (i.e., laboratory-confirmed TBEV infected patient with symptoms of CNS inflammation) and vaccination history to public health authorities. TBE VE was estimated using the screening method utilizing public health surveillance data from 2018 to 2022 and online household surveys of the general population on TBE vaccine uptake conducted in 2019-2022. Results: In 2018-2022, 3648 TBE cases were reported in the Czech Republic; 98.1% (3105/3166) of TBE cases with known vaccination history were unvaccinated. Among 42,671 persons surveyed from the general population who had known TBE vaccination history, 66.5% were unvaccinated. VE against TBE was 97.6% (95% confidence interval 95.7-98.7). When stratified by age group, VE was 97.1% (88.4-99.3) in 1-15 years of age, 97.9% (95.3-99.0) in 16-59 years of age, and 96.9% (90.5-99.0) in ≥60 years of age. TBE vaccination averted an estimated 1020 TBE cases in the Czech Republic from 2018 to 2022. Conclusions: This first published study with a full analysis of TBE VE in the Czech Republic showed that vaccination was highly effective for the prevention of TBE including in children, an age group with increasing TBE disease burden. Vaccination averted hundreds of TBE cases and hospitalizations despite the relatively low compliance with TBE vaccine recommendations. To prevent additional TBE cases in the Czech Republic, enhanced efforts to increase TBE vaccine uptake are needed.


Asunto(s)
Virus de la Encefalitis Transmitidos por Garrapatas , Encefalitis Transmitida por Garrapatas , Vacunación , Vacunas Virales , Encefalitis Transmitida por Garrapatas/prevención & control , Encefalitis Transmitida por Garrapatas/epidemiología , República Checa/epidemiología , Humanos , Persona de Mediana Edad , Adolescente , Adulto , Niño , Adulto Joven , Femenino , Masculino , Preescolar , Vacunas Virales/administración & dosificación , Virus de la Encefalitis Transmitidos por Garrapatas/inmunología , Anciano , Lactante
2.
Emerg Microbes Infect ; 12(2): 2278898, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37906509

RESUMEN

Tick-borne encephalitis (TBE) is an infection of the central nervous system caused by the tick-borne encephalitis virus (TBEV). TBE is endemic in parts of Europe and Asia. TBEV is transmitted to humans primarily by Ixodes ticks. There have been 5 TBE cases identified in Japan, all on the northern island of Hokkaido. Rodents with TBEV antibodies and Ixodes ticks have been identified throughout Japan, indicating that TBEV infection might be undiagnosed in Japan. Residual serum and cerebrospinal fluid (CSF) collected in 2010-2021 from 520 patients ≥1 year-of-age previously hospitalized with encephalitis or meningitis of unknown etiology at 15 hospitals (including 13 hospitals outside of Hokkaido) were screened by ELISA for TBEV IgG and IgM antibodies; TBEV infection was confirmed by the gold standard neutralization test. Residual serum was available from 331 (63.6%) patients and CSF from 430 (82.6%) patients; both serum and CSF were available from 189 (36.3%). Two patients were TBE cases: a female aged 61 years hospitalized for 104 days in Oita (2000 km south of Hokkaido) and a male aged 24 years hospitalized for 11 days in Tokyo (1200 km south of Hokkaido). Retrospective testing also identified a previous TBEV infection in a female aged 45 years hospitalized for 12 days in Okayama (1700 km south of Hokkaido). TBEV infection should be considered as a potential cause of encephalitis or meningitis in Japan. TBE cases are likely undiagnosed in Japan, including outside of Hokkaido, due to limited clinical awareness and lack of availability of TBE diagnostic tests.


Asunto(s)
Virus de la Encefalitis Transmitidos por Garrapatas , Encefalitis Transmitida por Garrapatas , Ixodes , Meningitis , Animales , Humanos , Masculino , Femenino , Encefalitis Transmitida por Garrapatas/diagnóstico , Encefalitis Transmitida por Garrapatas/epidemiología , Japón/epidemiología , Estudios Retrospectivos
3.
J Med Food ; 13(1): 123-30, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20136445

RESUMEN

A cell-based assay system was developed to evaluate the potential antioxidant and pro-oxidant effects of various dietary polyphenolic compounds based on the induction of p53 activity by hydrogen peroxide. A p53-luciferase reporter vector was stably transfected into NIH3T3 cells. Individual clones were isolated, and one clone (number 33) was selected that showed the highest induction levels with different generators of free radicals. Clone 33 was preincubated for 1 hour with 0, 0.1, 1.0, 10, 50, and 100 microM genistein, resveratrol, naringenin, quercetin, epicatechin gallate, and epigallocatechin-3-gallate and then treated with 40 microM hydrogen peroxide or left untreated for 4 hours. Cell lysates were prepared and assayed for luciferase activity. Results show that the effects on p53 activity by the different polyphenolics varied depending on the compound and concentration. Quercetin and genistein reduced p53 activity at 1.0 microM, whereas the other four compounds did not attenuate p53 activity. With the exception of naringenin, the other compounds increased p53 at the higher (50 microM or 100 microM) amounts, without added hydrogen peroxide, suggesting that these compounds can act as pro-oxidants or possibly stimulate p53 activity by another mechanism.


Asunto(s)
Antioxidantes/farmacología , Dieta , Flavonoides/farmacología , Radicales Libres/metabolismo , Estrés Oxidativo/efectos de los fármacos , Fenoles/farmacología , Extractos Vegetales/farmacología , Proteína p53 Supresora de Tumor/metabolismo , Animales , Relación Dosis-Respuesta a Droga , Genes Reporteros , Peróxido de Hidrógeno/metabolismo , Luciferasas , Ratones , Ratones Endogámicos , Células 3T3 NIH , Polifenoles , Proteína p53 Supresora de Tumor/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA